KR20140071472A - 간세포 암종을 포함하는 암의 저해제로서 그리고 간염 바이러스 복제의 저해제로서의 치환된 아미노티아졸 - Google Patents

간세포 암종을 포함하는 암의 저해제로서 그리고 간염 바이러스 복제의 저해제로서의 치환된 아미노티아졸 Download PDF

Info

Publication number
KR20140071472A
KR20140071472A KR1020147011691A KR20147011691A KR20140071472A KR 20140071472 A KR20140071472 A KR 20140071472A KR 1020147011691 A KR1020147011691 A KR 1020147011691A KR 20147011691 A KR20147011691 A KR 20147011691A KR 20140071472 A KR20140071472 A KR 20140071472A
Authority
KR
South Korea
Prior art keywords
pyridin
pyrimidin
thiazol
amine
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147011691A
Other languages
English (en)
Korean (ko)
Inventor
안드리아 쿠코나티
시아오동 수
티모시 엠. 블록
Original Assignee
인스티튜트 포 헤퍼타이티스 앤드 바이러스 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜트 포 헤퍼타이티스 앤드 바이러스 리서치 filed Critical 인스티튜트 포 헤퍼타이티스 앤드 바이러스 리서치
Publication of KR20140071472A publication Critical patent/KR20140071472A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147011691A 2011-10-04 2012-10-04 간세포 암종을 포함하는 암의 저해제로서 그리고 간염 바이러스 복제의 저해제로서의 치환된 아미노티아졸 Ceased KR20140071472A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542907P 2011-10-04 2011-10-04
US61/542,907 2011-10-04
PCT/US2012/058674 WO2013052613A1 (en) 2011-10-04 2012-10-04 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Publications (1)

Publication Number Publication Date
KR20140071472A true KR20140071472A (ko) 2014-06-11

Family

ID=48044139

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147011691A Ceased KR20140071472A (ko) 2011-10-04 2012-10-04 간세포 암종을 포함하는 암의 저해제로서 그리고 간염 바이러스 복제의 저해제로서의 치환된 아미노티아졸

Country Status (13)

Country Link
US (2) US20140249154A1 (https=)
EP (1) EP2763674A4 (https=)
JP (2) JP6240078B2 (https=)
KR (1) KR20140071472A (https=)
CN (1) CN103957908A (https=)
AU (1) AU2012318670B2 (https=)
BR (1) BR112014007963A2 (https=)
CA (1) CA2850779A1 (https=)
HK (1) HK1200361A1 (https=)
IL (1) IL231923A0 (https=)
PH (1) PH12014500724A1 (https=)
SG (1) SG11201401207XA (https=)
WO (1) WO2013052613A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9582896B2 (en) * 2011-09-02 2017-02-28 Qualcomm Incorporated Line tracking with automatic model initialization by graph matching and cycle detection
JP6329958B2 (ja) * 2012-11-07 2018-05-23 カルス セラピューティクス リミテッド 新規ヒストンデアセチラーゼインヒビターおよび治療におけるその使用
WO2014159938A1 (en) * 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
NZ714283A (en) 2013-05-10 2020-04-24 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
WO2016046759A2 (en) 2014-09-22 2016-03-31 Fratagene Therapeutics Ltd. Compositions and methods for treating friedreich's ataxia
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
MX2017013795A (es) * 2015-04-29 2018-03-21 Foresight Biotherapeutics Inc Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
US10913734B2 (en) * 2016-07-11 2021-02-09 Baruch S. Blumberg Institute Substituted aminothiazoles
EP3641772B1 (en) * 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
US20240025891A1 (en) * 2020-10-23 2024-01-25 Celgene Corporation Heterocyclic compounds and their use for treatment of helminthic infections and diseases
WO2025017207A1 (en) 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
WO2025151517A1 (en) * 2024-01-08 2025-07-17 Wavebreak Therapeutics Limited Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001237401B2 (en) * 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
KR100979988B1 (ko) * 2001-08-13 2010-09-03 얀센 파마슈티카 엔.브이. 2-아미노-4,5-삼치환 티아졸릴 유도체
JP2007530696A (ja) * 2004-03-30 2007-11-01 メルク　エンド　カムパニー　インコーポレーテッド アスパラギン酸プロテアーゼ阻害剤として有用な２−アミノチアゾール化合物
US20050227989A1 (en) * 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
WO2007103550A2 (en) * 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-hcv activity
WO2008083098A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators

Also Published As

Publication number Publication date
US20140249154A1 (en) 2014-09-04
HK1200361A1 (en) 2015-08-07
PH12014500724A1 (en) 2014-05-19
US20170066758A1 (en) 2017-03-09
AU2012318670A1 (en) 2014-05-22
EP2763674A1 (en) 2014-08-13
EP2763674A4 (en) 2015-04-29
JP6240078B2 (ja) 2017-11-29
JP2014528450A (ja) 2014-10-27
IL231923A0 (en) 2014-05-28
SG11201401207XA (en) 2014-05-29
AU2012318670B2 (en) 2017-09-07
WO2013052613A1 (en) 2013-04-11
JP2017149753A (ja) 2017-08-31
CN103957908A (zh) 2014-07-30
US10087173B2 (en) 2018-10-02
BR112014007963A2 (pt) 2013-04-11
CA2850779A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
KR20140071472A (ko) 간세포 암종을 포함하는 암의 저해제로서 그리고 간염 바이러스 복제의 저해제로서의 치환된 아미노티아졸
AU2013226013B2 (en) Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use
USRE47142E1 (en) Compounds and methods for treating inflammatory and fibrotic disorders
TWI434843B (zh) 激酶抑制劑及其使用方法
WO2021008338A1 (zh) 极光激酶抑制剂及其用途
HK1221952A1 (zh) 作为bet蛋白和极体样激酶的双重抑制剂的取代的二氢吡啶并[3，4-b]吡嗪酮
KR20160132470A (ko) 피페리딘-다이온 유도체
AU2009221134A1 (en) Pim kinase inhibitors and methods of their use
JP2022532719A (ja) Ａｃｓｓ２阻害剤およびその使用方法
KR20240095274A (ko) 프롤릴 히드록실라제 도메인-함유 단백질 (phd) 억제제 및 그의 용도
JP2011506494A (ja) 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
JP7369139B2 (ja) Ｐｉ３キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
JP5910976B2 (ja) 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
CA3171187A1 (en) Inhibitors of ulk1/2 and methods of using same
KR20230119124A (ko) 디클로로페놀 hsd17b13 억제제 및 이의 용도
WO2019050794A1 (en) IMIDAZOLIDINE COMPOUNDS
KR20250002427A (ko) Cdk9 억제제
EP3487498A1 (en) Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
KR20240125035A (ko) 이환 인다졸 글루코코르티코이드 수용체 길항제
US11834432B2 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
US10913734B2 (en) Substituted aminothiazoles
WO2020046975A1 (en) Methods of treating neurodegenerative diseases
WO2019136093A1 (en) Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
MX2012006863A (es) Nuevos derivados (heterociclo-tetrahidro-piridin)-(piperazinil)-1- alcanona y (heterociclo-dihidro-pirrolidin)-(piperazinil)-1-alcano na y su uso como inhibidores de p75.
KR20210024019A (ko) 탄키라아제 저해제로서의 1,2,4-트리아졸 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140429

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20141216

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170929

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190311

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I